{"id":"NCT03316300","sponsor":"Neurotech Pharmaceuticals","briefTitle":"A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A","officialTitle":"A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-24","primaryCompletion":"2022-08-31","completion":"2022-09-23","firstPosted":"2017-10-20","resultsPosted":"2024-09-24","lastUpdate":"2024-09-24"},"enrollment":120,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Macular Telangiectasia Type 2 (MacTel)"],"interventions":[{"type":"COMBINATION_PRODUCT","name":"NT-501","otherNames":[]},{"type":"PROCEDURE","name":"Sham Procedure","otherNames":[]}],"arms":[{"label":"NT-501","type":"EXPERIMENTAL"},{"label":"Sham","type":"SHAM_COMPARATOR"}],"summary":"This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the NT-501 implants in participants with macular telangiectasia type 2.","primaryOutcome":{"measure":"The Rate of Change in the Area of EZ Area of Loss From Baseline Through Month 24","timeFrame":"End point timeframe is through Month 24. Baseline, Month 6, 12, 16, 20 and 24. Month 6 was collected but not included in the primary analyses.","effectByArm":[{"arm":"NT-501","deltaMin":0.075,"sd":0.0123},{"arm":"Sham","deltaMin":0.166,"sd":0.0125}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":20,"countries":["United States","Australia","France","United Kingdom"]},"refs":{"pmids":["40693847"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":58},"commonTop":["Conjunctival haemmorhage","Dry eye","Delayed dark adaptation","Eye pain","Foreign body sensation in eyes"]}}